Press releaseGlobe Newswire
Pelthos Therapeutics
PTHS · NYSE American
$20.50+$0.24 (+1.18%)TodayMarket closed ·
Prev close $20.26
Latest news
- News
Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
- Press releaseGlobe Newswire
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- News
Pelthos Therapeutics Q1 2026 Earnings Call Transcript
- News
Earnings Scheduled For May 14, 2026
- Press releaseGlobe Newswire
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
- News
Earnings Scheduled For March 19, 2026
- Press releaseGlobe Newswire
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
- Press releaseGlobe Newswire
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
- Press releaseGlobe Newswire
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Press releaseBusiness Wire
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
- Press releaseGlobe Newswire
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
- Press releaseGlobe Newswire
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
- Press releaseGlobe Newswire
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
- Press releaseGlobe Newswire
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
- News
Earnings Scheduled For November 13, 2025
- NewsVandana Singh
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.